Diffuse Large B-cell Lymphoma
Conditions
Brief summary
This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.
Detailed description
The body surface area(BSA) on the date of every treatment cycle may be used as the same value of baseline BSA, if change of body weight is within 10% of baseline body weight. But, if there is a change of body weight more than 10% that of baseline, BSA should be recalculated. It will be repeated every 21 days. But the change of starting date of subsequent cycle and laboratory or radiologic tests may be allowed within 4 days from the scheduled date or delay due to toxicities. The RD-RCHOP treatment will be continued up to 6-8 cycles (or 3 cycles in case of stable disease(SD) or progressive disease(PD) after the first 3cycles) with duration of 21 days. Visit windows ± 4days in Treatment period.
Interventions
DRUGRituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Sponsors
Pusan National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed CD20 positive DLBCL 2. Age ≥ 65 years 3. Ann Arbor stage II, III and IV 4. No prior chemotherapy or radiotherapy for DLBCL 5. Performance status (ECOG) ≤ 2 6. At least one or more bidimensionally measurable lesion(s) * 2 cm by conventional CT * 1 cm by spiral CT skin lesion (photographs should be taken) ≥ 2 cm measurable lesion by physical examination ≥ 2 cm 7. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2DECHO without clinically significant abnormalities 8. Adequate renal function: serum creatinine level \< 2 mg/dL (177 μmol/L) 9. Adequate liver functions: Transaminase (AST/ALT) \< 3 X upper normal value (or \< 5 x ULN in the presence of DLBCL involvement of the liver) Bilirubin \< 2 X upper normal value (or \< 5 x ULN in the presence of DLBCL involvement of the liver) 10. Adequate BM functions: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL and platelet count ≥ 75,000/μL, unless abnormalities are due to bone marrow involvement by lymphoma 11. Life expectancy more than 6 months 12. A negative serum or urine pregnancy test prior to treatment must be available both for pre-menopausal women and for women who are \< 1years after the onset of menopause. 13. Informed consent
Exclusion criteria
1. Other subtypes NHL than DLCBL 2. Patients who transformed follicular lymphoma or other indolent lymphoma 3. Primary Central Nervous System (CNS) DLBCL 4. CNS involvement by lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks) in case of clinical suspicion of CNS involvement by lymphoma. Patients who have only had prophylactic intrathecal chemotherapy against CNS disease are eligible. 5. Patients with a known history of HIV seropositivity or HCV (+). Patients who have HBV (+) are eligible. However, primary prophylaxis using antiviral agents (i.e. lamivudine) is recommended for HBV carrier to prevent HBV reactivation during whole treatment period. 6. Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri 7. Pregnant or lactating women, women of childbearing potential not employing adequate contraception 8. Other serious illness or medical conditions i. Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry ii. History of significant neurologic or psychiatric disorders including dementia or seizures iii. Active uncontrolled infection (viral, bacterial or fungal infection) iv. Other serious medical illnesses 9. Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies) 10. Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year progression free survival rate | Time between the date of treatment start and the date of death due to any cause or date of disease progression, whichever came first, assessed up to 36 months |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate | Until the disease progression (maximum 3 years after completion of treatment, assessed up to 36 months( |
| Overall survival | Time between the date of treatment start and the date of death due to any cause or date of disease progression, whichever came first, assessed up to 36 months |
| Toxicity profile | From the date of first drug administration until the date of the 30th days |
Outcome results
None listed